phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Real-World FLOURISH Study Confirms Osimertinib Benefit in Chinese NSCLC

A large prospective real-world study in China has confirmed that first-line osimertinib provides substantial clinical benefit to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), including those who would have been excluded from pivotal clinical trials. The findings also reveal that patients carrying additional gene co-mutations experience significantly shorter survival, suggesting these individuals may require more intensive treatment approaches.

September 25, 2026


September 25 2026

September 24 2026

September 23 2026

September 22 2026

September 21 2026

September 18 2026

September 17 2026

September 16 2026

September 15 2026

September 14 2026

September 11 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy